Sign up
Pharma Capital
Market: AIM
52-week High/Low: 47.80p / 5.65p
Sector: Pharma & Biotech
Market Cap: 93.63M

Futura Medical is an innovative R&D company with a pipeline of products in late stage development. We are experts in transdermal delivery and have developed an advanced proprietary transdermal technology, DermaSys®. Our lead product MED2005, is a breakthrough topical treatment for erectile dysfunction currently in Phase 3 clinical trial with potential peak sales of $1bn1. Our strategy is to...

Futura Medical PLC

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in Futura Medical PLC

Futura Medical PLC Snapshot

Futura Medical is developing a portfolio of products in pain relief and sexual health. Our strategy is to develop our portfolio of innovative products for two large market categories, sexual health and pain, and then partner at the optimum time to generate most value.

Our Strategy Chart

Futura's innovation strategy applies advanced science to develop products with compelling commercial potential using our advanced proprietary transdermal technology.

Our research and development strategy

We focus exclusively on topically applied pharmaceutical drugs, ancillary medicinal substances and functional excipients for the over the counter and prescription markets. We only incorporate existing well-characterised chemical entities into our products. This strategy gives us a lower development risk profile compared with developing new chemical entities. As a result, the overall risk of the investment is reduced as our strategy increases the likelihood of regulatory approval and lowers the cost of development.

We specialise in sexual health and pain relief and have five core products in our development pipeline:

Sexual Heath



Pain relief





Board of Directors

John Clarke
Non-Executive Chairman and Chairman of Nomination Committee
Current roles: John Clarke became Chairman of Futura Medical plc in 2012. He is a member of the Nominations Committee and the Remuneration Committee. He is also the Non-Executive Chairman of Science in Sport plc and Kind Consumer Holdings Limited and a senior advisor to Helios Investment Partners LLP.

Past roles: Appointed President of GSK Consumer Healthcare in 2006, a position from which he stepped down in 2011. Under his leadership, GSK Consumer Healthcare became one of the fastest-growing companies in its industry. Non-executive Chairman of Quantum Pharma Plc.

Brings to the Board: Extensive experience of the healthcare sector, having worked at GSK for more than 35 years.


James Barder
Chief Executive
Current roles: James Barder joined the Group as Chief Executive in 2001. He assists the Remuneration Committee and the Nominations Committee (but is not a member of and does not vote on either). He has overall responsibility for all activities of the Group, is a principal contact for shareholder and investor relations matters and leads commercial negotiations. He first became involved with the Group in 1997.

Past roles: Managing Director of Aon Capital Markets Limited and Non-Executive Director of Lorega Limited. James has predominantly worked in the field of insurance and finance including firms he founded.

Brings to the Board: Over 25 years of experience in setting up, managing and running companies.


Angela Hildreth
Finance Director and Chief Operating Officer
Company Secretary
Current roles: Angela joined the company in February 2018. She leads the Group's finance, HR and IT functions, inputs into commercial and financial strategy, ensures its compliance procedures and is a principal contact for shareholder and investor relations matters.

Past roles: Senior financial roles in a diverse range of industries, including the past 7 years as UK Finance Director at Shield Therapeutics Plc (listed on AIM stock exchange).

Brings to the Board: Strategic and operational financial experience of developing and commercialising pharmaceutical products.


Ken James
Executive Director and Head of R&D
Current roles: Ken James joined the Board in April 2016. In November 2016 he was appointed Head of R&D. He oversees the development, regulatory and manufacturing strategies for the company's existing pipeline and the evaluation of early stage pipeline opportunities. He is a member of the Nominations Committee, the Remuneration Committee and the Audit Committee.

Past roles: Senior Vice President of Research and Development for GlaxoSmithKline Worldwide Consumer Healthcare, having worked in the UK and the United States.

Brings to the Board: Over 40 years' experience in the research, development and commercialisation of consumer healthcare products.


Jonathan Freeman, BA (Hons), MBA
Senior Independent Non-Executive Director and
Chairman of Remuneration Committee and Audit Committee
Current roles: Jonathan Freeman joined the Board in 2003 and was appointed Senior Independent Non-Executive Director in November 2003. He chairs the Audit Committee and the Remuneration Committee and is also a member of the Nominations Committee. He is also an Executive Director of Braveheart Investment Group plc, a Director of PhotonStar LED Group plc and a Non-Executive Director of European Wealth Group Limited.

Past roles: Director of Beeson Gregory, Chief Executive Officer of Syndicate Asset Management plc and a Director of Hume Securities plc.

Brings to the Board: Over 25 years of experience in the financial services sector, guidance on City regulatory matters, corporate finance and investor relations.

Share statistics (as at 19 November 2018)

Number of Ordinary Shares in issue (undiluted) 204,583,439
Number of Ordinary Shares subject to options 5,950,000
Maximum number of Ordinary Shares in issue (fully diluted) 213,778,252

The effect of the options, if all were exercised, would be to increase the issued share capital by 2.91% and raise £2,313,050 for the Company.

There are no restrictions on the transfer of Futura Medical plc shares.

Major shareholders (as at 19 November 2018)

Shareholders holding more than 3% of the share capital of Futura were:

Lombard Odier Asset Management (Europe) Limited 23.99%
T Adams 7.06%
RA Lamb 4.68%
WT Lamb Investments Limited 4.49%


Futura Medical Head Office

Surrey Technology Centre

40 Occam Road




Telephone: +44 (0) 1483 685670

Fax: +44 (0) 1483 685671

Email: [email protected]

Public relations and media

Optimum Strategic Communications

8 Devonshire Square



Tel: +44 (0) 203 950 9144

Email: [email protected]

Investor Contacts and Advisors


Nominated Adviser and broker

N+1 Singer

1 Bartholomew Lane





Arlington Business Park




Link Asset Services

The Registry

34 Beckenham Road



Principal solicitors

Square One Law

Anson House, Burdon Terrace

Newcastle upon Tyne



Patent attorneys

Withers and Rogers LLP

4 More London Riverside



Principal bankers


PO Box 160

12A North Street




View full FUM profile View Profile
View All

Market Reports Including FUM


Executive video interviews


© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.